12:00 AM
 | 
May 19, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/16 cls
Alexion (NASDAQ:ALXN) Jefferies Salveen Kochnover New Buy -1% $70.99
Kochnover set an $89 target. She believes robust sales of Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) will drive near- and long-term growth. Alexion markets the humanized mAb targeting C5 to treat PNH in the U.S. and Europe.
Amicus (NASDAQ:FOLD) Lazard Matthew Osborne Price target Buy 8% $10.69
Osborne lowered his target to $13 from $15 after Amicus amended the protocol for a six-month Phase II trial of Plicera isofagomine to treat Gaucher's disease, which he believes will delay the launch of the chaperone that binds to glucocerebrosidase until mid-2012 (see B19). He also lowered his FY12-FY14 Plicera revenue estimates to $56M, $122M and $223M from $76M, $151M and $268M, respectively.
Auxilium (NASDAQ:AUXL) Pacific Growth Kimberly Lee New Buy 1% $30.40
Lee set a $36 target. She believes Auxilium's Xiaflex (AA4500) is an attractive alternative to surgery and has the potential to become the standard of care for Dupuytren's disease. She expects Phase III data for the injectable form of collagenase ABC enzyme this quarter. Auxilium has exclusive rights to develop and commercialize Xiaflex from BioSpecifics...

Read the full 1294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >